Antipsychotics

Researchers in the U.S. and India reviewed the pharmacological treatment of schizophrenia since its introduction 50 years ago, trying to understand why it "remains...

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

MedPageToday reports that Janssen Pharmaceuticals omitted data from a 2003 study that connected Risperdal with serious side effects. Janssen was previously sued by the FDA for marketing Risperdal for off-label uses and settled for $2.2 billion in 2013. Earlier this year, a man with autism was awarded $2.5 million after growing breasts while on Risperdal. According to MedPage, documents from this latest case reveal missing data tables from a 2003 study “designed to ferret out potential adverse effects of long-term risperidone use.” The missing tables were related to elevated prolactin levels and side effects, including gynecomastia in men.

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.

Careful reductions in dosage levels of antipsychotic medications over time improved long-term rates of recovery and functional remission in patients diagnosed with a first-episode psychosis.

Research from the medical schools of Harvard University and the University of Melbourne, reported in the December International Journal of Eating Disorders, found that...

Researchers from London, writing in European Psychiatry, reviewed "all RCTs involving children and young people with a diagnosis of childhood onset schizophrenia comparing any...

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.

Evidence of duplicate publishing in articles analyzing data from clinical trials testing second-generation antipsychotics for depression

Antipsychotics are currently the predominant treatment for individuals diagnosed with schizophrenia, but there is an accumulating body of research that links the use of these drugs to structural abnormalities in the brain. A recent meta-analysis suggests that gray matter loss in the brain may depend on the dose and class of the antipsychotic.

The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.

Research published in the Journal of Clinical Psychiatry shows that of all 901 patients diagnosed with schizophrenia from July 2009 to June 2010 at a...

Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.

Reduced usage of antipsychotics in first-episode psychosis was associated with improved executive functioning.

Dopamine supersensitivity as a result of sustained antipsychotic treatment can lead to compulsive drug seeking and drug-taking behavior, according to the theory offered by...

Research published in the Journal of Psychiatric Practice finds that a "shared discussion of beliefs about medication between patient and care provider allows wider...

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

A study published today in the American Medical Association's journal JAMA Psychiatry reports that patients whose antipsychotic treatment was reduced or discontinued (DR) experienced a recovery...

One-third of adults with an intellectual or developmental disability are dispensed antipsychotics, despite having no existing psychiatric diagnosis.

A study released online today by the British Journal of Psychiatry shows that the clinical profile of neuroleptic malignant syndrome (NMS) is similar in 1st- v....

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Endogenous retroviruses, remnants of ancient infections that have become part of the human genome, have been associated with the development of schizophrenia. But researchers...

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.